SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of GenMark Diagnostics, Inc. (GNMK)

NEW YORK, Nov. 3, 2017

The investigation concerns whether GenMark and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On November 2, 2017, GenMark revealed its third quarter 2017 financial results. On a conference call with investors and analysts, GenMark's President and CEO, Hany Massarany said that revenue recognition for projected placements of ePlex was slowed by a lengthy customer evaluation and validation process prior to implementation of ePlex in routine clinical use. Following this news, GenMark stock dropped during intraday trading on November 3, 2017.

If you are aware of any facts relating to this investigation, or purchased GenMark shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/gnmk.  You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com